# Full-Life Technologies Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/full-life-technologies-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.full-life.com
- Total disclosed funding: $255M
- Latest round: Series D (May 18, 2026)
- Investors on record: 18

## About

Based in China, Full-Life Technologies operates as a medical service provider mainly engaged in the development, production, and commercialization of radiopharmaceuticals.Founded in 2021 and based in Shanghai, China, Full-Life Technologies is a medical company engaged in the development of nuclear therapy. The company's co-founder, chairman, and chief executive officer, Lanny Sun, served as partner and chief investment officer at Gordian Ventures. The branches were set up in Belgium and Germany. Full-Life Technologies is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. In May 2026, Full-Life Technologies raised USD 110 million in series D funding led by Vivo Capital, with participation from SK Biopharmaceuticals, TSG Capital, Yunion, Chengwei Capital, HSG, Junson Capital, Sky 9 Capital, Plaisance. The round was part of a larger USD 150 million series D and venture debt funding.

The company's business includes the production of radioisotopes and the development of a biological research platform for radiopharmaceutical therapy. Its radio technology platform contains the production and logistics of radiopharmaceutical drug products. The company generates revenue by doing research, development, production, and commercialization of radiopharmaceuticals and other related products.

The May 2026 funding will use to progress its clinical programs and build manufacturing capacity to support product supply.

## Funding rounds

- Series D, May 18, 2026, $110M — TSG Capital, Chengwei Capital, Vivo Capital, Junson Capital, Sky 9 Capital, HSG, Yunion, SK Biopharmaceuticals
- Series C, Sep 30, 2025, $50M — Chengwei Capital, Plaisance Capital, Junson Capital, Lapam Capital, HSG, Summer Capital, Gordian Ventures, Prosperity7, Hainan Zhenmai Private Equity Fund Management
- Series B, Jan 4, 2024, $47M — Chengwei Capital, Junson Capital, Sky 9 Capital, HSG, Summer Capital, Geuniom Group, Prosperity7
- Series A, May 26, 2022, $37M — Junson Capital, CD Capital, Shanhai Capital, HSG, Yinglian Health Industry Fund
- Seed, Dec 21, 2021, $10M — Chengwei Capital, Gordian Ventures

## Investors

- Chengwei Capital (https://capitalatlas.ai/funds/chengwei-capital) — Seed, Series B, Series C, Series D
- Gordian Ventures — Seed, Series C
- Junson Capital — Series A, Series B, Series C, Series D
- CD Capital — Series A
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series A
- HSG (https://capitalatlas.ai/funds/hsg) — Series A, Series B, Series C, Series D
- Yinglian Health Industry Fund — Series A
- Sky 9 Capital (https://capitalatlas.ai/funds/sky-9-capital) — Series B, Series D
- Summer Capital — Series B, Series C
- Geuniom Group — Series B
- Prosperity7 (https://capitalatlas.ai/funds/prosperity7) — Series B, Series C
- Plaisance Capital — Series C
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series C
- Hainan Zhenmai Private Equity Fund Management (https://capitalatlas.ai/funds/hainan-zhenmai-private-equity-fund-management) — Series C
- TSG Capital (https://capitalatlas.ai/funds/tsg-capital) — Series D
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series D
- Yunion — Series D
- SK Biopharmaceuticals — Series D